The role of natural killer cells in viral infections

Scandinavian Journal of Immunology

Volumn 46, Issue 3, 1997, Pages 217-224

  See, D M ^a   Khemka, P ^a   Sahl, L ^a   Bui, T ^a   Tilles, J G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CELL INTERACTION; CYTOLYSIS; HUMAN; HUMAN CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TARGET CELL; VIRUS CELL INTERACTION; VIRUS INFECTION;

EID: 0030750939     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-121.x     Document Type: Review

References (98)

1. Trinchieri G. Biology of natural killer cells. In: Dixon, FJ, ed. Advances in Immunology. San Diego, CA: Academic Press 1989; 187-303.
2. Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis 1994;18:(Suppl. 1):S157-9.
3. Mitchell WM, Forti RL, Vogler LB, Lawton AR, Gregg CR. Spontaneous and infection resistant natural killer cell anergy in AIDS. AIDS 1984;1:221-9.
4. Morita T, Tokue A, Minato N. Analysis of natural killer activity and natural killer cell subsets in patients with bladder cancer. Cancer Immunol Immunother 1990;32:191-4.
5. Struyf NJ, Snoeck HW, Bridts CH, DeClerk LS, Stevens WJ. Natural killer cell activity in Sjogrens syndrome and systemic lupus erythematosis stimulation with interferons and IL-2 and correlation with immune complexes. Ann Rheumatic Dis 1990;49:690-3.
6. Whiteside TL, Herberman RB. The role of natural killer cells in human disease. Clin Immunol Immunopathol 1989;45:182-7.
7. Tanigawa T, Araki S, Ishzu S, Morita T, Okazaki H, Minato N. Natural killer cell activity in workers exposed to benzidine and beta-naphtylamine. Br J Industrial Med 1990;47:338-41.
8. Holcombe RF. Interleukin-2-Induced cytotoxicity of Chediak-Higashi lymphocytes. Acta Haematol 1992;87:45-8.
9. Anderson DC, Schmalsteig FC, Finegold MJ. The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency; their quantitative definition and relation to leukocyte dysfunction and clinical features. J Infect Dis 1995;152:668-89.
10. Ritz J, Schmidt RE, Michon J, Hercend T, Schlossman SF. Characterization of functional surface structures on human natural killer cells. Adv Immunol 1988;42:181-211.
11. Ortaldo JR, Sharrow SO, Timonen T, Herberman RB. Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. J Immunol 1981;127:2401-9.
12. Scala G, Djeu JY, Allavena P et al. Cytokine secretion and noncytotoxic functions of human large granular lymphocytes. In: Lotzova E, Herberman RB. eds. Immunobiology of Natural Killer Cells, Vol. II. Boca Raton, FI: CRC Press, 1986;133-44.
13. Anegon I, Cuturi MC, Trinchieri G, Perussia B. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med 1988;167:452-72.
14. Trinchieri G, Matsuomoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med 1984;160:1147-69.
15. Storkus WJ, Dawson JR. Target structures involved in natural killing (NK): characteristics, distribution, and candidate molecules. Crit Rev Immunol 1990;10:393-416.
16. Reyburn H, Mandelboim O, Vales-Gomes M et al. Human NK cells: their ligands, receptors and functions. Immunol Rev 1997;1:55:119-25.
17. Vitale M, Sivori S, Pende D et al. Physical and functional independency of p70 and p58 natural killer cell (NK) cell receptors for HLA class I: their role in the definition of different groups of alloreactive NK cell clones. Proc Natl Acad Sci USA 1996;93:1453-7.
18. Yokohama W, Daniels B, Seaman W, Hunziker R, Margulies D, Smith H. A family of murine NK cell receptors specific for target cell MHC class molecules. Semin Immunol 1995;7:89-101.
19. Moretta A, Sivori S, Vitalle M et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 1995;182:875-84.
20. Bolhuis RL, Roozemond RC, van de Griend RJ. Induction and blocking of cytolysis in CD2+, CD3-NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50kD sheep erythrocyte receptor. J Immunol 1986;136:3939-44.
21. Ramos OF, Patarroyo M, Yefenof EI, Klein E. Requirement of leukocyte cell adhesion molecules (CD11a-c/CD18) in the enhanced NK lysis of iC3b-opsonized targets. J Immunol 1989;142:4100-4.
22. Scott CF, Bolander S, McIntyre G. Activation of human cytolytic cells through CD2/T11. Comparison of the requirements for the induction and direction of lysis of tumor targets by T cells and NK cells. J Immunol 1989;142:4105-12.
23. Harris DT, Kapur R, Frye C. A species-conserved NK cell antigen receptor is a novel vimentin-like molecule. Dev Comp Immunol 1992;16:395-403.
24. Newman RA, Warner JF, Dennert G. NK recognition of target structures: is the transferrin receptor the NK target structure: J Immunol 1981;133:1841-5.
25. Ryan J, Seaman W. Divergent functions of lectin-like receptors on NK cells. Immunol Rev 1997;155:79-89.
26. Lanier L, Chang C, Phillips J. Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol 1994;153:2417-28.
27. Ryan J, Niemi E, Nakamura M, Seaman W. NKR-P1A is a target-specific receptor that activates natural killer cell cytotoxicity. J Exp Med 1995;181:1911-15.
28. Arase H, Arase N, Saito T. Interferon gamma production by natural killer (NK) cells and NK 1.1 and T cells upon NKR-P1 cross-linking. J Exp Med 1996;183:2391-6.
29. Chang C, Rodriguez A, Carretero M, Lopez-Botet M, Phillips J, Lanier L. Molecular characterization of human CD94: a type-II membrane glycoprotein related to the C-type lectin superfamily. Europ J Immunol 1995;48:2433-7.
30. Alderson MR, Sassenfeld HM, Widmer MB. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J Exp Med 1990;172:577-87.
31. Chehimi J, Starr E, Frank I. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 1992;175:789-96.
32. Heron I, Holkand M, Moller-Larsen P, Berg K. The effect of interferon on lymphocyte-mediated effector cell functions: selective enhancement of natural killer cells. Cell Immunol 1979;42: 183-7.
33. Naume B, Gately MK, Desai BP, Sundan A, Espevik T. Synergistic effects of interleukin 4 and interleukin 12 on NK cell proliferation. Cytokine 1993;5:38-46.
34. Gatti G, Masera RG, Pallavicini L. Interplay in vitro between ACTH, endorphin, and glucocorticoids in the modulation of spontaneous and lymphokine-inducible human natural killer (NK) cell activity. Brain Behav Immun 1993;7:16-28.
35. De Martino M, Rossi, ME, Muccioli AT, Resti M, Vierucci A. Interferences of hepatitis B surface antigen with natural killer cell function. Clin Exp Immunol 1985;61:90-5.
36. Pricop L, Rabinowich H, Morel PA. Characterization of the Fcu receptor on human natural killer cells. Immunology 1993;151:3018-29.
37. Azzari C, Rossi ME, Resti M. VIP restores natural killer cell activity depressed by hepatitis B surface antigen. Viral Immunol 1992;5: 195-200.
38. Windebank KP, Abraham RT, Powis G, Olsen RA, Barna TJ, Leibson PJ. Signal transduction during human natural killer cells activation: inositol phosphate generation and regulation by cyclic AMP. J Immunol 1988;141:3951-7.
39. 2+ of human NK cells. J Immunol 1989;143:1058-65.
40. 2+ in FcIIIR (CD16)-induced transcription and expression of lymphokine genes. J Exp Med 1989;169:549-67
41. Leibson PJ, Midthun DE, Windebank KP, Abraham RT. Transmembrane signaling during natural killer cell-mediated cytotoxicity. J Immunol 1990;145:1498-504.
42. Cifone MG, Botti D, Festuccia C. Involvement of phospholipase A2 activation and arachidonic acid metabolism in the cytotoxic functions of rat NK cells. Cell Immunol 1993;148:247-58.
43. Salcedo TW, Azzoni L, Wolf SF, Perussia B. Modulation of perforin and granzyme messenger RNA expression in human natural killer cells. J Immunol 1993;151:2511-20.
44. Schmidt RE, Caulfield JP, Michon J. T11/CD2 activation of cloned human natural killer cells results in increased conjugate formation and exocytosis of cytolytic granules. J Immunol 1988;140:991-1002.
45. Fanger MW, Shen L, Graziano RF, Guyre PM. Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today 1989; 10:92-9.
46. Welsh RM, Brubaker JO, Vargas-Cortes M, O'Donnell CL. Natural killer (NK) cell response to virus infections in mice with severe combined immunodeficiency. The stimulation of NK cells and the NK cell-dependent control of virus infections occur independently of T and B cell function. J Exp Med 1991;173:1053-63.
47. Vella C, Festenstein H. Coxsackievirus B4 infection of the mouse pancreas: the role of natural killer cells in the control of virus replication and resistance to infection. J Gen Virol 1992;73:1379-86.
48. Godeny EK, Gauntt CJ. Involvement of natural killer cells in coxsackievirus B3-induced murine myocarditis. J Immunol 1986; 137:1695-702.
49. White LL, Smith RA. D variant of encephalomyocarditis virus (EMCV-D)-induced diabetes following natural killer cell depletion in diabetes-resistant male C57BL/6J mice. Viral Immunol 1990;3: 67-76.
50. Habu S, Akamatsu KI, Tamaoki N, Okumura K. In vivo significance of NK cell on resistance against virus (HSV-1) infections in mice. J Immunol 1984;133:2743-6.
51. Bukowski JF, Warner JF, Dennert G, Welsh RM. Adoptive transfer studies demonstrating the antiviral effects of NK cells in vivo. J Exp Med 1985;161:40-52.
52. Welsh RM. Regulation of virus infections by natural killer cells. Natl Immun Cell Growth Regul 1986;5:169-99.
53. Kast WM, Bluestone JA, Heemskerk MHM. Treatment with monoclonal anti-CD3 antibody protects against lethal Sendai virus infection by induction of natural killer cells. J Immunol 1990; 145:2254-9.
54. Stein-Streilein J, Guffee J. In vivo treatment of mice and hamsters with antibodies to asialo GMI increases morbidity and mortality to pulmonary influenza infection. J Immunol 1986;136:1435-41.
55. Yang Y, Lebrec H, Burleson G. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on pulmonary influenza titer and natural killer (NK) activity in rats. Fund Appl Toxicol 1994;23:105-31.
56. Orange J, Wang B, Cox T, Biron C. Requirement for natural killer cell produced interferon gamm in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. J Exp Med 1995;182:1045-56.
57. Wang J, Nichogiannopoulou A, Wu L, Sun L, Sharpe A, Bigby M, Georgeopoulos K. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros Null Mutation. Immunity 1996;5:537-49.
58. Inoue Y, Minasi P, Oh JO. The role of natural killer cells in murine cytomegalovirus eye infection. Invest Ophthalmol Visual Sci 1993; 34:1954-62.
59. Tay C, Welsh R. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol 1997;71:267-75.
60. Terada K, Kawano S, Yoshihiro K, Morita T. Natural killer cell activity in herpes zoster in children without underlying disease. Scand J Infect Dis 1993;25:524-31.
61. Ihara T, Kamiya H, Starr SE, Arbater AM, Lange B. Natural killing of varicella-zoster virus (VZV)-infected fibroblasts in normal chil-dren, children with VZV infections, and children with Hodgkin's disease. Acta Paediatr 1989;31:523-8.
62. Saibara T, Maeds T, Onishi S, Yamamota Y. Depressed immune functions in the early phase of varicella-zoster virus reactivation. J Med Virol 1993;39:242-5.
63. Canessa A, Chatterjee S, Whitley RJ, Prasthofer EF, Grossi CE, Tilden AB. Individual NK cell clones lyse both tumor cell targets and herpes simplex virus-infected fibroblasts in the absence of interferon. Viral Immunol 1990;3:217-24.
64. Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med 1994;180:537-43.
65. Borysiewicz LK, Rodgers B, Morris S, Graham S, Sissons JG. Lysis of human cytomegalovirus infected fibroblasts by natural killer cells: demonstration of an interferon-independent component requiring expression of early viral proteins and characterization of effector cells. J Immunol 1985;134:2695-701.
66. Bandyopadhyay S, Oh SH, Michelson S, Miller DS, Virelizier JL, Starr SE. Natural killing of fibroblasts infected with low-passage clinical isolates of human cytomegalovirus. Clin Exp Immunol 1988; 73:11-16.
67. Borysiewicz LK, Graham S, Sissons JG. Human natural killer cell lysis of virus-infected cells. Relationship to expression of the transferrin receptor. Europ J Immunol 1986;16:405-11.
68. Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL. Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol 1987;139:3802-7.
69. Kundu SK, Menezes J. Interleukin-2 induced killer cell activity against Epstein-Barr virus-immortalized human B cells. Immunol Lett 1989;20:299-304.
70. Echevarria S, Casafont F, Miera M et al. Interleukin-2 and natural killer activity in acute type B hepatitis. Hepato-Gastroenterology 1991;38:307-10.
71. Actis GC, Ponzetto A, D'Urso N. Chronic active hepatitis B. Interferon-activated natural killer-like cells against a hepatoma cell line transfected with the hepatitis B. virus nucleic acid. Liver 1991; 11:106-13.
72. Di Bisceglie AM, Fong TL, Fried MW. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993;88:1887-92.
73. Perrillo RP, Schiff ER, Davis GL. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
74. Lok ASF, Ma OCK, Lau JYN. Interferon alfa therapy in patients with chronic hepatitis B virus infection: effects of hepatitis B virus DNA in the liver. Gastroenterology 1991;100:756-61.
75. Caselmann WH, Meyer M, Scholz S, Hofschneider PH, Koshy R. Type I interferons inhibit hepatitis B virus replication and induce hepatocellular gene expression in cultured liver cells. J Infect Dis 1992;166:966-71.
76. Hata K, Zhang XR, Iwatsuki S, Van Thiel DH, Herberman RB, Whiteside TL. Isolation, phenotyping and functional analysis of leukocytes from human liver. Clin Immunol Immunopathol 1990; 56:401-19.
77. Donohue SM, Wonke B, Hoffbrand AV. Alpha interferon in the treatment of chronic hepatitis C infection in the thalassaemia major. Br J Haematol 1993;83:491-7.
78. Wonke B, Donohue SM, Hoffbrand AV, Scheuer PJ, Brown D, Dusheiko G. Recombinant alpha 2B interferon (IFN) in the treatment of chronic hepatitis C disease in thallassemia major (TM). Bone Marrow Transplantation 1993;121(Suppl 1):24-5.
79. Jenkins M, Mills J, Kohl S. Natural killer cytotoxicity of human immunodeficiency virus-infected cells by leukocytes from human neonates and adults. Pediatr Res 1993;33:469-74.
80. Cai Q, Huang L, Rappociolo G, Rinaldo CR. Natural killer cell responses in homosexual men with early HIV infection. J Acquired Immune Deficiency Syndrome 1990;3:669-76.
81. Scott-Algara D, Vuillier F, Cayota A, Dighiero G. Natural killer (NK) cell activity during HIV infection: a decrease in NK activity is observed at the clonal level and is not restored after in vitro long-term culture of NK cells. Clin Exp Immunol 1992;90:181-7.
82. Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infection. FASEB J 1996;10:258-66.
83. Tyler DS, Stanley SD, Nastala CA. Alterations in antibody-dependent cellular cycotoxicity during the course of HIV-1 infection. J Immunol 1990;144:3375-84.
84. Rook AH, Masur H, Lane HI et al. IL-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983;72:398-403.
85. Interferon Alpha Study Group. A randomized placebo-controlled trial of recombinant human interferon alfa-2a in patients with AIDS. J Acquired Immunodeficiency Syndrome 1988;1:111-18.
86. Kovacs J, Baseler M, Deware RJ. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995;332:567-75.
87. Malcjczyk J, Malejczyk M, Majewski S, Orth G, Jablonska S. NK-cell activity in patients with HPV16-associated anogenital tumors: defective recognition of HPV 16-harboring keratinocytes and restricted unresponsiveness to immunostimulatory cytokines. Int J Cancer 1993;54:917-21.
88. Lusso P, Malnati M, Garzino-Demo A, Crowley R, Long E, Gallo R. Infection of natural killer cells by human herpesvirus 6. Nature 1993; 362:458-62.
89. York IA, Johnson DC. Direct contact with herpes simplex virus-infected cells results in inhibition of lymphokine-activated killer cells because of cell-to-cell spread of virus. J Infect Dis 1993;168: 1127-32.
90. Haliotis T, Roder J, Klein M. Chediak-Higashi gene in humans. I. Impairment of natural killer function. J Exp Med 1980;151:1039-48.
91. Aoki T, Usuda Y, Miyakoshi H, Tamura K, Herberman RB. Low natural killer syndrome: clinical and immunologic features. Nat Immun Cell Growth Regul 1987;6:116-28.
92. Okamura K, Furukawa K, Nakakuki M, Yamada K, Suzuki M. Natural killer cell activity during pregnancy. Am J Obstet Gynecol 1984;149:396-9.
93. Stein MD, Gamble DN, Klimpel KD, Herndon DN, Klimpel GR. Natural killer cell defects resulting from thermal injury. Cell Immunol 1984;86:551-6.
94. Pedersen BK, Ullum H. NK cell response to physical activity: possible mechanisms of action. Med Sci Sport Exercise 1994;26: 140-6.
95. Fergulio C, Zambello R, Trentin L. Cytotoxic in vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy. Cancer 1992;69:2525-31.
96. Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984; 63:305-9.
97. Bidga J, Mysliwska J, Baran W, Hellmann A, Mysliwiski A. Interleukin-2 and interteron alpha induced natural killer cell activity as a marker of progression in hairy cell leukemia. Leukemia and Lymphoma 1993;9:371-6.
98. Biron CA, Byron KS, Sullivan JL. Severe herpes virus infections in an adolescent without natural killer cells. N Engl J Med 1989;320: 1731-5.